Mumbai: Drug manufacturer Ranbaxy Laboratories Saturday said it has recalled all lots of Nitrofurantoin Capsules, used in the treatment of infections.

In a filing to the Bombay Stock Exchange, Ranbaxy Labs said Ranbaxy Pharmaceutical Inc (RPI), a wholly-owned US subsidiary of the company, has recalled all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, United States Pharmacopeia (USP) 100 mg, available in the market there.

USP is an official public standards —setting authority for all prescription and over-the-counter medicines and other health care products manufactured or sold in the US.

The company has said it is conducting a voluntary recall of all lots of capsules. “Although certain lots of the products were determined to not be in conformity with the approved laboratory specifications, the company decided to recall all the lots, as a matter of abundant caution,” the filing added.

The recall is being conducted in coordination with the US Food and Drug Administration (FDA) and would be a retail level recall, it added.

Ranbaxy Pharmaceuticals Inc is engaged in the sale and distribution of generic and branded prescription products in the US, it said.